Psychotropic Medications Not Monitored for Behavior and Sleep Effectiveness
Summary
The facility failed to ensure psychotropic medications were monitored in accordance with physician orders and its Chemical Restraints and Psychotropic Medication Management policy for two residents. One resident with diagnoses including diabetes mellitus, Alzheimer’s disease, major depression, and psychosis was receiving Abilify 15 mg daily for psychosis and hearing voices that were not there. Although the care plan and psychiatry evaluation indicated continued medication management and behavior monitoring, the psychiatry evaluation did not identify the specific behavior to monitor, and the record contained no documented evidence that the resident’s psychotic symptoms were monitored. A second resident with diagnoses including falls, Alzheimer’s disease, and a left leg fracture was ordered quetiapine fumarate 25 mg at bedtime for insomnia. The resident’s H&P stated the resident lacked capacity to understand and make decisions. The MAR, progress notes, and other reviewed records did not contain documented evidence that the resident’s hours of sleep were monitored after the medication was started. The care plan included interventions to administer medications as ordered and monitor side effects and effectiveness, and the consent form stated the medication was intended to increase hours of sleep and continue only as long as necessary. During interviews, the DON confirmed that the first resident’s behavior of hearing voices should have been monitored and documented, and that such monitoring helps determine whether the medication can be reduced or discontinued. LVN 3 and the DON also stated that the second resident’s hours of sleep should have been monitored to determine whether quetiapine was effective and whether it was causing excessive drowsiness. The facility policy stated that licensed nurses would review the indication, behavior monitoring, and related adverse side effects, and that the interdisciplinary team would ensure monitoring for adverse consequences and effectiveness of medications.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.